CAH
Cardinal Health, Inc.
CAH's fundamentals are mixed: revenue grew 10%, while its operating margin held steady at 1%. At 36x earnings, it's trading above its usual 30x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CAH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
CAH's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $130 | -53% |
| Forward | 21x | $278 | — |
| Fair | 30x | $231 | -17% |
| Current | 36x | $278 | — |
| Expensive | 44x | $341 | +23% |
Historical ranges are pointers, not guarantees.
CAH's PE is in its expensive range at 36x. If earnings grow as analysts expect, today's price would be 21x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CAH's earnings to grow, with its revenue and profitability holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.12 | +70% |
| Q3 2026 | $7.73 | +17% |
| Q2 2026 | $7.23 | +12% |
| Q1 2026 | $6.54 | +2.5% |
| Q4 2025 | $6.95 | +30% |
| Q3 2025 | $6.63 | +30% |
| Q2 2025 | $6.45 | +88% |
| Q1 2025 | $6.38 | +182% |
| Q4 2024 | $5.33 | +109% |
CAH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $67.5B | +5.5% |
| Q2 2026 | $63.7B | +5.8% |
| Q1 2026 | $60.9B | +11% |
| Q4 2025 | $65.6B | +19% |
| Q3 2025 | $64B | +22% |
| Q2 2025 | $60.2B | +0.8% |
| Q1 2025 | $54.9B | -0.1% |
| Q4 2024 | $55.3B | -3.8% |
CAH's revenue has grown year over year for six quarters in a row: $67.5B last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.1% | +0.1 points |
| Q2 2026 | 1.1% | +0.4 points |
| Q1 2026 | 0.8% | -0.5 points |
| Q4 2025 | 1.1% | +0.1 points |
| Q3 2025 | 1% | -0.1 points |
| Q2 2025 | 0.7% | 0 points |
| Q1 2025 | 1.3% | +0.7 points |
| Q4 2024 | 1% | +0.2 points |
CAH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CAH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +43% |
| Q2 2026 | $1.4B | +10% |
| Q1 2026 | $1.7B | -40% |
| Q4 2025 | $555M | +$1.1B |
| Q3 2025 | $865M | +$2.6B |
| Q2 2025 | $1.3B | -31% |
| Q1 2025 | $2.8B | +$3B |
| Q4 2024 | -$499M | -146% |
CAH generated $4.9B in free cash flow over the past year, up 10% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CAH on cash flow, with more consistent year-over-year improvement.
CAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -4M shares |
| 1 year | -2.5% | -6M shares |
| 3 years | -6.8% | -17M shares |
| 5 years | -19% | -56M shares |
| Available history | -21% | -61M shares |
CAH has 233M diluted shares, down 2.5% from a year ago, with $1.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $350M |
| Q1 2026 | $250M |
| Q4 2025 | $383M |
| Q3 2025 | $375M |
| Q2 2025 | — |
| Q1 2025 | $375M |
| Q4 2024 | $15M |
CAH spent $1.5B buying back its own shares over the past year, up 94% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CAH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.0x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
CAH's net debt is about a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 81.9 | Overbought |
CAH's weekly RSI is 71 (overbought) and its Stochastic is 82 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CAH PE vs Healthcare Sector
| Metric | CAH | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 73 | 29 | 44 pts above |
CAH is trading at 36x earnings, a 39% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $248.8 | 12% above |
| 20 week MA | $239.7 | 16% above |
| 50 week MA | $222.0 | 25% above |
| 100 week MA | $185.9 | 50% above |
| 200 week MA | $141.9 | 96% above |
CAH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $53.8 | +4.5% |
| 2021 | $53.8 | $50.8 | -5.7% |
| 2022 | $50.8 | $80.1 | +58% |
| 2023 | $80.1 | $100.8 | +26% |
| 2024 | $100.8 | $119.1 | +18% |
| 2025 | $119.1 | $208.3 | +75% |
| 2026 YTD | $208.3 | $278.1 | +34% |
CAH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.